

## WORKING GROUP MEETING MINUTES: ILD/IPF Working Group 16<sup>th</sup> March 2023

**REG Summit Lisbon** 

Meeting details			
Meeting location	Lisbon Marriott Hotel, Lisbon / MS Teams		
Meeting date	Thursday 16 <sup>th</sup> March 2023		
Meeting time	15.00-16.00 local time		
Chair(s)	Pilar Rivera-Ortega		
Attendees	Gina Amanda Arata Azuma Xavíer Jaumont Janet Johnston Graham Lough	Pilar Rivera-Ortega Paola Rottoli Stefan Stanel Michael Walker	
Objectives			
1	Update on vMDT project		
2	New project ideas		

Items		
Update on vMDT project	<ul> <li>The group was updated on the vMDT project via presentation highlighting some results. <ul> <li>Surveys closed in January with 363 unique centres, data analysis and final report in progress.</li> <li>A poster presentation was given at ICLAF 2022.</li> <li>An abstract has been submitted to ERS Congress 2023.</li> </ul> </li> <li>Three publications from the project were suggested: <ul> <li>Main article</li> <li>Perspectives article: Comparison with phase 1 results (MDTs in pre/post-COVID)</li> <li>A letter to the editor highlighting inequalities of health access.</li> </ul> </li> </ul>	
Potential future projects	<ul> <li>Suggestions for several future projects were discussed:</li> <li>1) Barriers in access to technology in vMDTs in LMICs <ul> <li>A next step for the vMDT project</li> <li>Potential Delphi</li> </ul> </li> <li>2) Pulmonary hypertension in ILD</li> </ul>	

Respiratory Effectiveness Group, ESpace North, 181 Wisbech Road, Littleport, Ely, Cambridgeshire, CB6 1RA, UK enquiries@effectivenessevaluation.org | effectivenessevaluation.org



Respiratory Effectiveness Group

	<ul> <li>Retrospective study (centres from vMDT project willing to participate) – need to know data we want (e.g., DLCO) and inclusion criteria.</li> <li>Develop probability matrix/tool to correlate ILD &amp; PH (likelihood of PH-ILD)</li> <li>Could follow up with prospective study in LMIC.</li> <li>Interstitial lung abnormalities risk for ILD</li> <li>Prospective study</li> <li>Risk factors pathway</li> <li>Identify which risk factors: patients should go to ILD centre following ILAS.</li> <li>Cost-Effectiveness studies</li> <li>Potential CE models for vMDT and ILAS studies.</li> </ul>
Action Points	<ul> <li>Potential meeting with steering committee to refine project ideas.</li> <li>Research proposals to be developed for project ideas.</li> <li>Consult with Brett McQueen from REG Cost Effectiveness working group about CE study model requirements.</li> <li>Manuscripts to be written for the vMDT project.</li> </ul>

Respiratory Effectiveness Group, ESpace North, 181 Wisbech Road, Littleport, Ely, Cambridgeshire, CB6 1RA, UK enquiries@effectivenessevaluation.org | effectivenessevaluation.org